Italian pharmaceutical company Chiesi Group has secured exclusive global rights to Archer Biotechnologies’ ABO-101 gene editing therapy for primary hyperoxaluria type 1 (PH1), an ultra-rare kidney disease. The deal involves up to $2.1 billion in payments, including $115 million upfront and near-term milestones, plus royalties. This marks Chiesi’s initial foray into gene editing therapeutics. Arbor retains rights for limited additional targets and anticipates transformative impacts on rare disease treatments.